Abstract
Tumor size is one of the decisive parameters for the efficacy of conventional radiation therapy. From experimental and clinical data this seems also to be true for systemic radiotherapy, such as radioiodine therapy in thyroid cancer (Malone 1975) or radioimmunotherapy (RIT) with labeled monoclonal antibodies (MAbs) (Thedrez et al. 1989; Chatal et al. 1989) In general, it may be stated that the smaller the tumor size, the greater the chance of controlling it. However, for a very small tumor, the contrary may be the case in systemic radiotherapy: due to the limited range of the radionuclides used, a considerable proportion of the energy may be deposited outside the tumor and tumoricidal doses may not be achieved. Thus, in the situation of minimal residual disease (MRD) the chance of cure may be lessened.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akabani G, Poston JW (1991) Absorbed dose calculation to blood and blood vessels for internally deposited radionuclides. J Nucl Med 32: 830–834
Akabani G, Poston JW, Bolch WE (1991) Estimates of beta absorbed fractions in small tissue volumes for selected radionuclides. J Nucl Med 32: 835–839
Chatal JF, Saccavini JC, Gestin JE, Thedrez P, Curtet C, Kremer M, Guerreau D, Nobile D, Fumoleau P, Guillard Y (1989) Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 49: 3089–3094
Ford RL, Nelson WR (1978) The EGS code system. National Technical Information Service, Springfeld (Stanford Linear Accelerator Center, report no 210 )
Fraker PJ, Speck JC (1980) Protein and cell membrane iodinations with a sparingly soluble chloramine l,3,4,6-tetra-chlor-3,6-diphenyl-glycoluryl. Biochem Biophys Res Commun 80: 849–857
Gimbrone MA, Leapman SB, Cotran RS, Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261–276
ICRU (1979) Methods of assessment of absorbed dose in clinical use of radionuclides. International Commission on Radiation Units and Measurements, Washington (Report no 32 )
James F (1980) Monte Carlo theory and practice. Rep Prog Phys 43: 1145–1189
Kalos H, Whitlock PA (1986) Monte Carlo method, vol. 1. Basics. Wiley, New York
Loevinger R, Berman MA (1968) Scheme for absorbed dose calculations for biologically distributed radionuclides. J Nucl Med 9 Suppl 1: 9–14
Loevinger R, Berman MA (1976) A revised scheme for calculation and absorbed dose from biologically distributed radionuclides. New York: Society of Nuclear Medicine, New York tMIRD pamphlet, no 1
Mach J-P, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso J-D, Schreyer M, Girardet C, Accola RS, Carrel S (1981) Use of radiolabeled monoclonal anti- CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 2: 239–249
Malone JF (1975) The radiation biology of the thyroid. Curr Top Radiat Res Q 10: 263–268
Nelson WR, Hirayama H, Rogers DWO (1985) The EGS4 code system. Stanford Linear Accelerator Center, Stanford (SLAC report 265 )
Rogers DWO (1984) Low-energy electron transport with EGS. Nucl Instrum Methods 227: 535–548
Schmid U, Schirrmacher V, Momburg F, Matzku S (1993) Preferential antibody targeting of small lymphoma metastases in the absence of primary tumor. Eur J Cancer 29: 217–225
Sullivan D, Siva JS, Cox CE, Haagensen DE, Harris CC, Briner WH, Wells SA (1982) Localisation of I-131-labeled goat and primate anti-carcinoembryonic antigen ( CEA) antibodies in patients with cancer. Invest Radiol 17: 350–355
Thedrez P, Saccavini JC, Nobile D, Simoen JP, Guerreau D, Gestin JF, Curtet C, Kremer M, Chatal FF (1989) Biodistribution of indium-111-labeled OC125 monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinoma. Cancer Res 49: 3081–3086
Wessels BW, Rogues RD (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11: 638–645
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Sautter-Bihl, ML., Herbold, G., Bihl, H. (1996). Minimal Residual Disease: a Target for Radioimmunotherapy with 131I-labeled Monoclonal Antibodies? Some Dosimetric Considerations. In: Sautter-Bihl, ML., Bihl, H., Wannenmacher, M. (eds) Systemic Radiotherapy with Monoclonal Antibodies. Recent Results in Cancer Research, vol 141. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79952-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-79952-5_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79954-9
Online ISBN: 978-3-642-79952-5
eBook Packages: Springer Book Archive